Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 543-546
DOI: 10.4103/ijmpo.ijmpo_214_19
Original Article

A Multicenter Retrospective Study to Evaluate Safety and Efficacy of Tocopheryl Polyethylene Glycol Succinate Docetaxel in Various Cancers

Shirish Alurkar
1   Apollo CBCC Cancer Care, Gandhinagar, Gujarat, India
,
Chanchal Goswami
2   Medical Superspeciality Hospital, Kolkata, West Bengal, India
,
Kamlesh Bokil
3   Dwidal Nursing Home, Pune, Maharashtra, India
,
Nirmal Raut
4   Jupiter Hospital, Thane, Maharashtra, India
,
Govind Babu
5   HCG Bangalore Institute of Oncology, Bengaluru, Karnataka, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction

In order to overcome the polysorbate induced hypersensitivity reactions with chemotherapy drugs, novel drug-delivery mechanisms have been developed in the last decade. D-alpha-tocopheryl polyethylene glycol succinate (TPGS) is formed by esterification of alpha-tocopheryl succinate and polyethylene glycol 1000.

Materials and Methods

This was a real-world retrospective analysis designed to evaluate safety and efficacy of TPGS-docetaxel in various cancers. Patients hospitalized between June 2018 and May 2019 were included in the data set. While the efficacy was assessed by the Response Evaluation Criteria in Solid Tumors criteria, safety was assessed by the National Cancer Institute Common Terminology Criteria-adverse event (AE) criteria.

Results

A total of 61 patients who received at least one dose of TPGS-docetaxel were incorporated into the analysis set. The dose of TPGS docetaxel ranged from 20 mg/m2 to 120 mg/m2, commonly prescribed dose being 75 mg/m2. While 25 (40.98%) patients had a partial response, 17 (27.86%) patients had stable disease. Five (8.19%) patients progressed and 4 (6.55%) patients died during the chemotherapy, which was adjudicated to be unrelated to the drug as opined by the treating clinician. AE were reported in 42 patients in the safety data set. There were no AEs pertaining to hypersensitivity reported during the study. One AE of Grade 3 hand foot syndrome was encountered.

Conclusion

The preliminary evidence suggests that the novel TPGS-based docetaxel formulation is efficacious in various cancers, and importantly, it has an enhanced safety profile, as it is devoid of polysorbate 80 induced hypersensitivity reactions.

Keywords

Breast cancer - docetaxel - hypersensitivity reaction - non-small cell lung cancer - tocopheryl polyethylene glycol succinate


Publication History

Received: 21 October 2019

Accepted: 01 June 2020

Article published online:
17 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55
    CrossrefPubMedGoogle Scholar
  • 2 Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: A review. Anticancer Drugs 2007; 18: 95-103
    CrossrefPubMedGoogle Scholar
  • 3 Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: A comprehensive review. Clin Rev Allergy Immunol 2015; 49: 177-91
    CrossrefPubMedGoogle Scholar
  • 4 Schwartzberg LS, Navari RM. Safety of polysorbate 80 in the oncology setting. Adv Ther 2018; 35: 754-67
    CrossrefPubMedGoogle Scholar
  • 5 Vasey PA, Atkinson R, Coleman R, Crqaford M, Cruikshank M, Eggleton P. et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001; 84: 170-8
    CrossrefPubMedGoogle Scholar
  • 6 Docetaxel Prescribing Information. United States Food and Drug Administration. 2014 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202356s000lbl.pdf Available from: [Last accessed on 2020 Jan 16]
    PubMed
  • 7 Neophytou CM, Constantinou AI. Drug delivery innovations for enhancing the anticancer potential of Vitamin E isoforms and their derivatives. Biomed Res Int 2015; 2015: 584862
    CrossrefPubMedGoogle Scholar
  • 8 Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33: 4889-906
    CrossrefPubMedGoogle Scholar
  • 9 Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci 2013; 49: 175-86
    CrossrefPubMedGoogle Scholar
  • 10 Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550-6
    CrossrefPubMedGoogle Scholar
  • 11 Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 2012; 33: 3494-501
    CrossrefPubMedGoogle Scholar
  • 12 Zhu H, Chen H, Zeng X, Wang Z, Zhang X, Wu Y. et al. Co-delivery of chemotherapeutic drugs with Vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 2014; 35: 2391-400
    CrossrefPubMedGoogle Scholar
  • 13 Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 185-7
    Google Scholar
  • 14 Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E. et al. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 1994; 5: 468-70
    CrossrefPubMedGoogle Scholar
  • 15 Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL. et al. B. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8
    CrossrefPubMedGoogle Scholar
  • 16 Youk HJ, Lee E, Choi MK, Lee YJ, Chung JH, Kim SH. et al. Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J Control Release 2005; 107: 43-52
    CrossrefPubMedGoogle Scholar
  • 17 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al. New response evaluation criteria in solid tumours: Revised RECIST Guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
    CrossrefPubMedGoogle Scholar
  • 18 Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V. et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81
    CrossrefPubMedGoogle Scholar
  • 19 Suvarna VR. Real world evidence (RWE) – Are we (RWE) ready?. Perspect Clin Res 2018; 9: 61-3
    CrossrefPubMedGoogle Scholar
  • 20 Figgitt DP, Wiseman LR. Docetaxel: An update of its use in advanced breast cancer. Drugs 2000; 59: 621-51
    CrossrefPubMedGoogle Scholar
  • 21 Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO. et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-201
    CrossrefPubMedGoogle Scholar
  • 22 Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: Facts and fiction. Pharm Res 2013; 30: 1729-34
    CrossrefPubMedGoogle Scholar
  • 23 Shahar E, Hassoun G, Pollack S. Effect of Vitamin E supplementation on the regular treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004; 92: 654-8
    CrossrefPubMedGoogle Scholar
  • 24 Yamada K, Hung P, Yoshimura K, Taniguchi S, Lim BO, Sugano M. Effect of unsaturated fatty acids and antioxidants on immunoglobulin production by mesenteric lymph node lymphocytes of Sprague-Dawley rats. J Biochem Tokyo 1996; 120: 138-44
    CrossrefPubMedGoogle Scholar